Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Accumulated Expenses (2016 - 2020)

Medifast's Accumulated Expenses history spans 7 years, with the latest figure at $16.9 million for Q4 2020.

  • For Q4 2020, Accumulated Expenses rose 62.82% year-over-year to $16.9 million; the TTM value through Dec 2020 reached $16.9 million, up 62.82%, while the annual FY2020 figure was $16.9 million, 62.82% up from the prior year.
  • Accumulated Expenses reached $16.9 million in Q4 2020 per MED's latest filing, up from $10.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $16.9 million in Q4 2020 to a low of $301000.0 in Q3 2016.
  • Average Accumulated Expenses over 5 years is $7.4 million, with a median of $6.1 million recorded in 2017.
  • Peak YoY movement for Accumulated Expenses: soared 321.35% in 2016, then dropped 15.77% in 2018.
  • A 5-year view of Accumulated Expenses shows it stood at $4.8 million in 2016, then surged by 38.41% to $6.6 million in 2017, then decreased by 15.77% to $5.5 million in 2018, then soared by 87.68% to $10.4 million in 2019, then surged by 62.82% to $16.9 million in 2020.
  • Per Business Quant, the three most recent readings for MED's Accumulated Expenses are $16.9 million (Q4 2020), $10.4 million (Q4 2019), and $5.5 million (Q4 2018).